文章摘要
刘东梅,张 剑,张兵兵,马彦娥,李小峰.参芪扶正注射液联合索拉非尼对晚期原发性肝癌的疗效及对患者VEGF、TNF-α、IFN-γ水平的影响[J].,2019,19(22):4287-4290
参芪扶正注射液联合索拉非尼对晚期原发性肝癌的疗效及对患者VEGF、TNF-α、IFN-γ水平的影响
Effect of Shenqi Fuzheng Injection Combined with Sorafenib on Advanced Primary Liver Cancer and Its Effect on VEGF, TNF-α and IFN-γ Levels in Patients
投稿时间:2019-05-28  修订日期:2019-06-23
DOI:10.13241/j.cnki.pmb.2019.22.018
中文关键词: 晚期原发性肝癌  参芪扶正注射液  索拉非尼  血管内皮生长因子  瘤坏死因子-α  γ-干扰素
英文关键词: Advanced primary liver cancer  Shenqi fuzheng injection  Sorafenib  Vascular endothelial growth factor  Tumor necrosis factor  Interferon-γ
基金项目:陕西省自然科学基金项目(20140517)
作者单位E-mail
刘东梅 榆林市第一医院 肿瘤科 陕西 榆林 719000 yuanfeiyishi@sina.com 
张 剑 榆林市第一医院 肿瘤科 陕西 榆林 719000  
张兵兵 榆林市第一医院 肿瘤科 陕西 榆林 719000  
马彦娥 延安大学第二附属医院 肿瘤科 陕西 榆林 719000  
李小峰 榆林市第一医院 肿瘤科 陕西 榆林 719000  
摘要点击次数: 0
全文下载次数: 0
中文摘要:
      摘要 目的:探讨参芪扶正注射液联合索拉非尼(SOR)治疗晚期原发性肝癌(PLC)的临床效果及对患者血管内皮生长因子(VEGF)、肿瘤坏死因子(TNF)-α、γ-干扰素(IFN-γ)水平的影响。方法:选取我院2015年3月~2017年3月收治的116例晚期PLC患者,采取随机数字表法均分为两组。对照组采取SOR进行分子靶向治疗,观察组在此基础上加用参芪扶正注射液辅助治疗。比较两组的临床疗效,治疗前后VEGF、TNF-α、IFN-γ水平的变化及不良反应的发生情况。结果:治疗3个月后,观察组临床获益率与有效率分别为81.0%、39.7%,较对照组(63.8%、20.7%,P<0.05)均明显上升。两组血清VEGF随治疗时间的延长而逐渐下降(P<0.01),且观察组治疗1、3个月后的VEGF低于对照组同期(P<0.05);两组血清TNF-α、IFN-γ水平均随治疗时间的延长而逐渐升高(P<0.01);且与对照组同期相比,观察组治疗1、3个月后以上指标均显著更高(P<0.01)。观察组不良反应率为43.1%,与对照组(62.1%)比较明显降低(P<0.05)。结论:参芪扶正注射液联合索拉非尼治疗晚期原发性肝癌的疗效显著,可能与其显著改善血清中VEGF、TNF-α、IFN-γ水平有关,同时其减毒效果较佳,可作为晚期原发性肝癌临床治疗的一种较为理想的用药方案。
英文摘要:
      ABSTRACT Objective: To investigate the clinical efficacy of shenqi fuzheng injection combined with sorafenib (SOR) on the advanced primary liver cancer (PLC) and effect on the vascular endothelial growth factor(VEGF), tumor necrosis factor (TNF)-α, interferon (IFN)-γ levels. Methods: The subjects of this study were selected from 116 cases of patients with advanced PLC admitted in our hospital from March 2015 to March 2017. The 116 cases were evenly divided into two groups on the basis of random time table. The control group was given SOR molecular targeted therapy, while the observation group was administrated with shenqi fuzheng injection based on the control group. The clinical efficacy, changes of Karnofsky (KPS) score, serum TNF-α, IFN-γ levels before and after treatment as well as the incidence of adverse reactions were compared between the two groups. Results: At three months after treatment, the clinical benefit rate and effective rate of observation group were 81.0% and 39.7%, which were significantly increased as compared with thoseof the control group (63.8% and 20.7%) (P<0.05). The serum VEGF of the two groups decreased gradually with the prolongation of treatment time (P<0.01), and the VEGF of the observation group after 1 and 3 months of treatment was lower than that of the control group at the same time (P<0.05); The levels of serum TNF-α and IFN-γ in both groups increased gradually with the prolongation of treatment time (P<0.01). Compared with the control group, the above indexes in the observation group were significantly higher after 1 and 3 months of treatment (P<0.01). The incidence of adverse reactions in the observation group was 43.1%, which was much lower than 62.1% of the control group (P<0.05). Conclusion: Shenqi Fuzheng Injection combined with sorafenib has significant therapeutic effect on advanced primary liver cancer, which may be related to the significant improvement of serum VEGF, TNF-α and IFN-γ levels. Meanwhile, it has better attenuation effect and can be used as an ideal medication scheme for clinical treatment of advanced PLC.
查看全文   查看/发表评论  下载PDF阅读器
关闭